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mutations in the genes that encode the enzymatic ma-
chinery of mismatch repair (Leach et al., 1993; Bronner
et al., 1994; Jirciny, 1994; Papadopoulos et al., 1994).
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These defects lead to an increased rate of mutagenesis²Department of Pathology
with widespread changes throughout the genome of theUT Southwestern Medical Center
affected individual (Ionov et al., 1993; Parsons et al.,Dallas, Texas 75235±9133
1993). One locus that is mutated in HNPCC encodes the
type II transforming growth factor-b (TGFb) receptor
(Markowitz et al., 1995).Summary
TGFb signals have many reported functions including
the ability to inhibit the proliferation of cells such asTGFb-related growth factors have been implicated in
colonic epithelium (Derynck, 1994; Liu et al., 1997). Sig-a variety of developmental and physiological pro-
naling by TGFb superfamily ligands is mediated by thecesses in organisms ranging from nematodes to mam-
Smad family of intracellular proteins (Graff et al., 1996).mals. TGFb transduces its signal to the interior of the
Smad2, Smad3, and Smad4 transduce signals from thecell via Smad2, Smad3, and Smad4. We report the
TGFb receptor. Upon activation of the TGFb receptor,cloning and targeted disruption of the mouse Smad3
Smad2 and/or Smad3 are phosphorylated and com-
gene. Smad3 mutant mice are viable and fertile. Be-
plexed with Smad4; thereafter, thecomplex translocates
tween 4 and 6 months of age, the Smad3 mutant mice to the nucleus and alters gene expression (Derynck and
become moribund with colorectal adenocarcinomas. Zhang, 1996; Massague, 1996; Wrana and Attisano,
The neoplasms penetrate through the intestinal wall 1996; Heldin et al., 1997).
and metastasize to lymph nodes. Theseresults directly Many colorectal cancers are resistant to TGFb. In ad-
implicate TGFb signaling in the pathogenesis of colo- dition, somatic loss-of-function mutations, in the genes
rectal cancer and provide a compelling animal model encoding the type II TGFb receptor, Smad2, and Smad4
for the study of human colorectal cancer. have been found in a subset of human colorectal can-
cers (Markowitz et al., 1995; Eppert et al., 1996; Thiaga-
Introduction lingam et al., 1996). Recently, a germline mutation in the
type II TGFb receptor has been reported in a patient
Cancers of the colon and rectum (colorectal cancer) are with colorectal cancer (Lu et al., 1998). Taken together,
a major cause of morbidity and mortality (Cohen et al., these data support an association between colorectal
1997). The majority (.95%) of colorectal cancers are cancer and loss-of-TGFb signaling.
adenocarcinomas derived from colonic epithelium. The Mice with inactivating mutations in the loci for the
mortality from colorectal cancer has changed relatively TGFb ligands, the TGFb receptor, Smad2, or Smad4 did
not develop colorectal cancer when the mutation waslittle over the past 50 years (Tomlinson et al., 1997;
present in the heterozygous state (Shull et al., 1992;Bresalier and Kim, 1998). This emphasizes the need for
Kulkarni et al., 1993; Dickson et al., 1995; Kaartinen ettherapies based upon a greater understanding of the
al., 1995; Oshima et al., 1996; Sanford et al., 1997; Sirardmolecular mechanisms that underlie colorectal cancer.
et al., 1998; Waldrip et al., 1998; Yang et al., 1998). WhenTo design rational treatments, the genes responsible for
the mutations were bred to homozygosity, the mice diedthe malignancies must be sought out and animal models
in utero or shortly after birth. This early lethality likelydeveloped.
precluded tumor formation and, therefore, these knock-Current models for colorectal adenocarcinoma impli-
out mice did not shed light on the role of TGFb signalingcate serial genetic alterations as the basis of cancer
and carcinogenesis. However, these studies did not ad-formation. The identification of multiple mutations in
dress the function of Smad3.colorectal cancer has been aided by the natural history
To study the possible role of Smad3 in developmentof the disease, which appears to progress through a
and/or tumorigenesis, we inactivated the gene in miceseries of steps. The disease progresses from normal to
by homologous recombination. Homozygous mutantshyperplastic colonic epithelium, to benign adenomatous
are viable but spontaneously form colorectal adenocar-polyps, to invasive and then metastatic carcinoma. It is
cinomas. These colorectal cancers are deeply invasive,thought that each of these changes is a consequence
penetrate through all layers of the intestinal wall, and
of a defined genetic event. Mutations of single genes
metastasize to lymph nodes. These findings demon-
predispose to formation of colorectal cancer in two fa-
strate a role for Smad3 in carcinogenesis and provide
milial syndromes, familial adenomatous polyposis (FAP) an animal model for the study of colorectal cancer.
and hereditary nonpolyposis colorectal cancer (HNPCC)
(Kinzler and Vogelstein, 1996; Tomlinson et al., 1997). Results
Individuals with FAP develop hundreds to thousands of
benign colorectal polyps due to a germline mutation in Cloning and Targeted Inactivation
the adenomatous polyposis coli (APC) gene (Groden et of the Mouse Smad3 Locus
al., 1991; Nishisho et al., 1991). HNPCC is caused by Degenerate oligonucleotides were used as polymerase
chain reaction (PCR) primers to amplifyand clone Smad-
specific sequences from mouse E8.5 cDNA as described³To whom correpondence should be addressed.
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Figure 1. Targeted Disruption of Smad3 by Homologous Recombi-
nation
(A) Schematic drawing of the wild-type (WT) Smad3 locus, the tar-
geting vector, and the mutant allele. IRES-LacZ and the neomycin
selectable marker are inserted into exon 2 (black box) of Smad3 to
generate a null allele. The location of the hybridization probes (Probe
A and Probe B) for Southern analysis are illustrated. B, BglII; S, SstI;
R, EcoRI.
(B) Southern blot analysis of ES clones. To hybridize with the 59
Figure 2. LacZ Staining of Wild-Type and Smad3 Heterozygousprobe (Probe A), the DNA was digested with BglII. The wild-type
Mice(WT) allele produced a 9.0 kb fragment, and the targeted allele (KO)
E11.5 embryos (A) wild type and (B) heterozygotes; (C) wild typeproduced a 14.0 kb fragment. Lanes 1 and 4 are recombinants.
and (D) heterozygous mutant colon, viewed from the luminal side.(C) Southern blot analysis on genomic DNA from littermates of a
Smad3 heterozygote (1/-) mating. Tail DNA, obtained from 3-week-
old pups, was digested with EcoRI and probed with the 39 probe
(Probe B); wild-type, 6.5 kb; mutant, 5.0 kb. Wild-type, (1/1); hetero- of the G418-FIAU resistant ES colonies exhibited a mu-
zygote, (1/-); homozygous mutant, (2/2)
tant (14 kb) Smad3 band upon Southern blot analysis
(Figure 1B). A 39 external probe verified these results
(Graff et al., 1996). These fragments were then used to (not shown). Four of the recombinant ES cell colonies
screen a murine 129/Sv genomic phage library, and a were injected into C57BL/6 blastocysts, each of which
15 kb genomic clone was isolated. Sequence analysis transmitted the mutant allele into the germline (Fig-
identified a 191 bp stretch that, when translated, exhib- ure 1C).
ited absolute amino acid conservation with the second
exon of the rat and human Smad3 genes (data not
Smad3 Is Expressed Embryonically
shown).
and in Colonic Epithelium
A targeting vector was constructed and designed to
The presence of the ªknocked-inº LacZ reporter gene
disrupt the second exon of the Smad3 locus (Figure 1A).
within the Smad3 coding sequence (Figure 1A) permit-
In addition, a LacZ gene was introduced into exon 2 of
ted b-galactosidase staining to analyze endogenousthe Smad3 gene, together with an internal ribosomal
expression of Smad3 in embryos and adults. Smad3 isentry site (IRES), to permit translation of the b-galactosi-
expressed in many developing tissues with highest lev-dase reporter from the interrupted Smad3 transcript
els in mesenchymal derivatives (Figure 2B). Of note,(Figure 1A). This strategy was designed to create a null
Smad3 is expressed in the adult colon, with highestallele for several reasons. First, the IRES-LacZ-Neo in-
levels in the muscularis propria and the submucosa andsertion into the second exon should truncate the gene
lower levels in the epithelium (Figure 2D). Thus, Smad3such that the carboxyl-terminal active domain of Smad3
is a widely expressed TGFb signaling intermediate.would not be produced (Baker and Harland, 1996; Liu
et al., 1996; Heldin et al., 1997). Second, the IRES-LacZ-
The Recombinant Smad3 Allele BehavesNeo cassette is inserted at the region where point muta-
as a Recessive Alleletions create loss-of-function Smad proteins (Eppert et
The germline chimeras were bred with 129/Sv femalesal., 1996; Schutte et al., 1996). Finally, sequence analysis
to generate an inbred 129/Sv Smad32/1 mouse strainindicated that alternative splicing around exon 2 would
and also to C57BL/6 females to generate F1 hybridshift the open reading frame (see below).
(129/Sv 3 C57BL/6) heterozygotes. Heterozygous miceTwo hundred eighty-eight G418-FIAU resistant ES cell
(Smad32/1) from both backgrounds were viable and fer-clones were isolated and screened for diagnostic South-
tile (Figures 1C and 4). The heterozygotes have beenern blot patterns with a 59 probe external to the recombi-
nation cassette (Figures 1A and 1B). Forty-three (15%) observed for up to nine months with no apparent signs
Smad3 Mutant Mice Develop Colorectal Cancer
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of altered phenotype compared to wild-type littermates
(not shown). Thus, in two different genetic backgrounds,
the mutant allele behaves as a recessive trait that is
only phenotypically manifest in the homozygous condi-
tion (see below).
To characterize the nature of the mutation, we exam-
ined expression from the mutant allele using RT-PCR
with a battery of primers that span the Smad3 open
reading frame (Figures 3A and 3B). Figure 3B shows the
location of the primers with respect to the exon 2±LacZ
insertion (shaded). RT-PCR analysis of RNA extracted
from E14.5 wild-type, heterozygous, and homozygous
mutant littermates showed evidence for only one tran-
script generated from exon 1 that spliced around the
targeted exon (Figure 3A). This aberrant transcript in-
cluded exon 1 (P1/3), excluded exons 2 and 3 (P9/10;
P6/7b), and included the remaining exons (P7a/8; and
P1/8 lower 1 kb band). The resultant aberrantly spliced
mutant transcript migrated as a slightly smaller band,
due to the loss of exons 2 and 3, compared to the wild-
type band on Northern blots (not shown) using a full-
length probe. We did not detect evidence for any addi-
tional Smad3 transcripts from the mutant locus.
We cloned the mutant Smad3 transcript toexamine its
molecular and functional properties. Sequence analysis
revealed aberrant splicing from exon 1 to exon 4 re-
sulting in an altered reading frame that terminated nine
amino acids downstream of the exon 1 to 4 splicing
event. Thus, in the unlikely event that a truncated pep-
tide is translated from the aberrant transcript, the 68
amino acids of exon 1 would be present together with
nine additional missense amino acids. Figure 3. Molecular Analysis of the Smad3 Mutant Allele
To determine if the mutant 77±amino acid peptide had (A) RT-PCR analysis showing an aberrant transcript, lacking exons
activity or perturbed the functions of other Smad family 2 and 3, produced from the mutant allele. Oligonucleotide primers,
illustrated in (B), were used for PCR to assess the transcripts pro-proteins, we tested its function in Xenopus laevis, a
duced in a wild-type (1/1), a heterozygote (1/-), and a homozygousmodel system for the study of TGFb and Smad signaling
mutant (2/2). A Smad3 cDNA plasmid was a positive control (Ctr).(Graff et al., 1996; Graff, 1997). We microinjected mRNA
b-actin served as loading control.that encoded the Smad3 mutant peptide into 1-cell Xe-
(B) RT-PCR strategy and sequence of the mutant transcript.
nopus embryos. The microinjected embryos had no phe- Positions of the primers, exons 1, 2, and 3 (E1, E2, E3) and the
notypic differences compared to wild-type sibling em- targeted deleted portion of exon 2 (shaded) are illustrated. The
mutant transcript was cloned by RT-PCR with primers 1 and 8.bryos (Figure 3C). To further characterize the function
Sequence analysis indicated splicing (downward arrow) from theof the mutant peptide, we utilized the animal cap assay.
first to the fourth exon that resulted in premature termination.Animal caps are fated to become ciliated epidermis or
(C) Expression of mutant Smad3 peptide had no effect on Xenopusskin; however, their fate can be changed to mesoderm
embryos. mRNA encoding the mutant Smad3 peptide (Smad3 Mut,
by activating Smads or to neural tissue by inhibiting 2 ng) was injected into the animal pole of 1-cell stage embryos. The
TGFb signaling (Baker and Harland, 1996; Graff et al., embryos were allowed to develop to a tadpole stage and photo-
graphed. Embryos injected with the mutant peptide were identical1996; Graff, 1997; Suzuki et al., 1997). When the mutant
to sibling control embryos.peptide was expressed in the animal cap, neither meso-
(D) The mutant Smad3 peptide had neither positive nor inhibitorydermal (muscle actin and globin) nor neural (NCAM)
function. Synthetic mRNAs were injected into the animal pole ofmarkers were induced (Figure 3D). Together, these re-
1-cell stage embryos, and animal caps were explanted at the blas-
sults indicate that the mutant peptide had neither posi- tula stage and cultured until stage 27. Total RNA was harvested
tive nor negative activity. To directly determine if the and analyzed by RT-PCR. The mutant Smad3 peptide (S3 mut, 2ng)
mutant peptide had dominant negative activity, we coin- did not induce mesodermal (M. actin, globin) or neural (NCAM) mark-
ers. Coinjection of Smad2 (2 ng) or Smad5 (2 ng) with mutant Smad3jected the mutant Smad3 with Smad2 or Smad5. In the
(2 ng) did not block Smad2 or Smad5 activity. EF-1a, ubiquitouslyanimal cap assay, coinjection is a method to determine
expressed, was a loading control (Krieg et al., 1989). RNA fromwhether the mutant Smad3 inhibits either the wild-type
embryos was a positive control; 2RT is identical to the embryo lane
injected Smad or endogenous Smad4 (Candia et al., except reverse transcriptase was omitted; control animal caps did
1997). We found that Smad2 induced the expression of not express mesodermal or neural markers.
muscle actin, and this expression was not altered by
coinjection of the mutant Smad3 (Figure 3D). Similarly,
Xenopus assays, the Smad3 mutant peptide had nothe presence of the mutant Smad3 had no effect on the
activity when injected alone and did not appear to inter-Smad5 induction of globin (Figure 3D). Equivalent data
were obtained with Smad1 (not shown). Therefore, in fere with Smad1, Smad2, Smad4, nor Smad5 function.
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Figure 4. Smad3 Homozygous Null Mice Are
Small and Have Decreased Survival
(A) Photograph of a heterozygous and a rep-
resentative inbred homozygous (top) Smad3
mutant at 5 months of age.
(B) Weight plots of 2-month-old male 129/Sv
mice. Wild-type (WT, n 5 10), heterozygous
(Het, n 5 9), and homozygous (KO, n 5 6).
gms, grams.
(C and D) Survival curves of inbred (C) and
hybrid (D) Smad3 mice.
These data are consistent with the mouse recessive mice. In both genetic backgrounds, however, the homo-
zygous mutant mice had significantly shortened life spansphenotype and support the notion that the targeted
Smad3 mutation is a null. compared to wild-type or heterozygous littermates (Fig-
ures 4C and 4D). The decrease in life span was more
pronounced in the inbred background, consistent withHomozygous Smad32/2 Mice Are Viable
Homozygous mutant Smad3 mice were generated from the presence of modifier loci.
both the inbred and hybrid Smad3 mouse strains by inter-
crossing the appropriate heterozygotes. Southern blot
(Figure 1C) and PCR-based analysis (not shown) of Smad3 Mutant Mice Develop Colorectal Tumors
We analyzed a cohort of 10 wild-type, 38 heterozygous,weanlings demonstrated that the homozygous mutant
mice were viable. In the hybrid background, genotypic and 12 homozygous inbred129/Sv mice. As thehomozy-
gous mutant mice aged beyond 18 weeks, they exhibitedanalysis of several litters revealed the following number
of progeny: 37 (26%) wild-type, 71 (50%) heterozygotes, signs of distress including fur-ruffling and lethargy (not
shown). By 24 weeks, rectal prolapse was observed inand 33 (23%) nulls. In the inbred genetic strain, we
found 27 (24%) wild-type, 58 (52%) heterozygous, and 75%(9/12) of Smad3 mutants (Figures 5Aand 5B).These
mutant mice also had distended abdomens and internal26 (24%) null progeny. This is consistent with the ex-
pected Mendelian ratios in both backgrounds. Thus, the examination revealed dilated large and small bowels
suggestive of colonic obstructions (Figure 5C).Smad32/2 mutants proceeded normally through embry-
onic development. Between 18 and 24 weeks, 100% (12/12) of inbred
Smad32/2 mutants demonstrated signs of distress, andOne hundred percent of the Smad32/2 homozygotes
did exhibit several overt phenotypes when compared all had evidence of tumor formation. Ten of the Smad3
mutant mice were studied in detail. Inspection of otherto their heterozygote or wild-type littermates (Figure 4).
In both the hybrid (129/Sv 3 C57BL/6) and inbred (129/ organs and tissues revealed no apparent differences
from wild-type or Smad3 heterozygous littermates. OneSv) backgrounds, null mutants are approximately 20%-
30% smaller than heterozygous or wild-type littermates exception is that lymph nodes in several mutant animals
were enlarged. To examine the large bowels of the mu-(Figures 4A and 4B), and the males exhibit a more pro-
nounced size reduction than do the females (not shown). tant mice in greater detail, we removed the gastrointesti-
nal tracts en bloc. In all specimens examined, multipleA second characteristic phenotype of the mutant pups
is a peculiar rounded posture suggestive of possible lesions were observed, exclusively in the large intestine
(Figures 5D and 5E, Table 1). Figure 5 shows typicalskeletal abnormalities (Figure 4A, not shown). Analysis
of several mutant skeletons confirmed the proportional examples of the gross morphology of the intestines. In
some specimens, large masses were observed in thesize reduction in the mutants, but no obvious defects
were detected to account for the altered posture of the proximal region of the colon (Figure 5D, Table 1). In
others, large masses were present in the distal end ofhomozygotes (not shown).
The adult Smad3 homozygous mutant mice were fer- the bowel (Figure 5E, Table 1). Smaller lesions were
detected in the intervening colon (Figures 5D and 5E,tile and produced homozygous litters, albeit at reduced
efficacy compared to wild-type or Smad3 heterozygous Table 1). Some of the tumors obstructed the lumen of
Smad3 Mutant Mice Develop Colorectal Cancer
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the neoplastic glands were more irregular than those
observed in theprevious tumor (compare Figure 6F to 6B
or 6C). The neoplastic glands had ruptured and released
mucin into the supporting stroma (Figure 6F), and we
also detected a marked desmoplastic reaction (Figure
6F). These are characteristics observed in human colo-
rectal cancers (Fenoglio-Preiser et al., 1989; Bresalier
and Kim, 1998). Consistent with themore atypical nature
of this neoplasm was the deeper penetration of the neo-
plastic cells into the muscle layer where they formed
distinct glands (Figure 6E). The Smad3 mutant mice also
contained highly aggressive tumors (Figures 6G-6I).
These aggressive tumors invaded freely through all lay-
ers of the bowel forming large mucin-filled glands and
mucous lakes on the surface of the intestine (Figure 6G).
In addition, the neoplastic cells formed branched glands
and nests of back-to-back glands (Figures 6H and 6I).
Again, theneoplastic glands were surroundedand sepa-
rated by an expanded desmoplastic stroma (Figure 6H).
Table 1 summarizes the colorectal neoplasms ana-
lyzed in ten 129/Sv inbred Smad3 homozygous mutant
mice. Careful examination of the small intestines in theFigure 5. Colorectal Abnormalities Detected in Smad3 Null Mice
mutant mice both grossly and by serial sections has not(A) Rectal prolapse (arrow) in a Smad3 mutant mouse.
(B) Colorectal region of the mouse shown in (A). Rectal prolaspe revealed any abnormalities. In contrast, 100% of the
(arrow) and distended bowel (arrowhead) at the site of intraluminal Smad3 mutant mice had colorectal adenocarcinomas
tumor. (Table 1). We detected early stage hyperproliferative or
(C) Abdominal distension of a Smad3 mutant mouse. A mass lesion
adenomatous lesions that had little or no evidence of(arrow) in the proximal colon. Proximal to the mass, the cecum and
penetration (not shown). For the purpose of this table,the small intestine are dilated due to the obstructing lesion.
however, we only included tumors containing neoplastic(D) View of the upper and lower intestine of the Smad3 null mouse
shown in (C). Multiple tumors (arrows) with two large tumors at the cells that invaded into the submucosa, a depth of inva-
proximal end of the colon. Distal (bottom) to the masses, the caliber sion sufficient for the diagnosis of adenocarcinoma. The
of the intestine is normal. Proximal (top) to the tumors the intestines majority of the neoplasms were moderately to welldiffer-
are dilated. entiated with both glandularand cellular atypia. On aver-(E) Multiple tumors (arrows) present in the colon of a Smad3 mutant
age, the mutant mice contained four readily apparentmouse. The proximal (top) and distal (bottom) masses are larger
masses that penetrated into at least the submucosathan the lesions in the intervening bowel.
(Table 1). In addition, approximately one-third of the
tumors invaded through all layers of the bowel wall (Ta-
the intestine as illustrated by the dilation of the bowel ble 1). The distribution of the cancers was asymmetric
proximal to the masses (Figures 5D and 5E). with a preponderance of the tumors located at the ends
of the bowel (Table 1). The average size of the tumors
Smad3 Mutant Mice Develop a Spectrum was approximately 0.7 cm with the larger lesions present
of Adenocarcinomas at either end of the lower intestine and the smaller
To determine the nature of the colorectal masses, we masses located in the intervening colon (Table 1). The
examined the tumors histologically. Examination of the finding of a wide range of tumors within a single mouse,
sections revealed a wide range of tumor size from 0.1 including lesions that appear to be polyps, suggests
to 2.5 cm (Table 1). By microscopic analysis, a spectrum that individual animals exhibit multiple stages of the
of tumors that ranged from hyperplastic lesions and natural history of tumorigenesis.
adenomatous polyps (not shown) to cancerous lesions
with progressive degrees of atypia was observed, and Smad32/2 Tumors Contain APC
extent of invasion was documented (Figure 6, Table 1). and Are Hyperproliferative
Figures 6A-6C illustrate a lesion with a limited depth The APC gene has been implicated in human colon
of neoplastic invasion. The neoplasticcolonic epithelium cancer, and mice with mutations in this gene exhibit
formed a plaque-like mass that is distinct from the adja- polypoid lesions albeit primarily in the small, rather than
cent normal mucosa (Figure 6A). Focally, in the base of large, intestine (Su et al., 1992). To determine whether
the crypts, there is evidence of increased mitotic figures loss of APC occurred in the Smad3 neoplastic process,
coupled with loss of the normal cellular polarity. In addi- we examined APCexpression by immunohistochemistry
tion, the glands are abnormally branched and dilated with carboxy- and amino-terminal APC antibodies. Adja-
(Figures 6B and 6C). This tumor extended into and cent to the tumors, both antibodies detected APC stain-
through the submucosa and the neoplastic glands abut- ing confined to the apical and lateral region (Figure 7A).
ting the muscle wall (Figure 6B). In a typical example of In contrast, APC expression is widespread throughout
a more aggressive tumor (Figures 6D-6F), the glandular the cancers (Figure 7B). Thus, loss of APC does not
atypia was more dramatic than that noted above and appear to be a contributing factor to the emergence of
neoplasia in Smad3 mutant mice.resulted in numerous mucin-filled cysts. Furthermore,
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Table 1. Summary of Colorectal Neoplasms in Smad32/2 129/Sv Mice
Location
Mouse Proximal Middle Distal
Number Sex Tumors (cm) (cm) (cm) Depth of Invasion
1 M 1 0.5 submucosa
2 0.5 submucosa
3 0.2 serosa
4 0.3 serosa
2 F 1 1.5 serosa
2 0.5 submucosa
3 0.5 submucosa
4 0.2 submucosa
3 M 1 0.5 submucosa
2 0.5 serosa
4 M 1 0.5 submucosa
2 1.0 submucosa
3 0.2 submucosa
4 0.5 submucosa
5 1.0 submucosa
5 M 1 0.8 submucosa
2 0.8 serosa
3 0.5 submucosa
4 0.1 serosa
5 0.5 submucosa
6 0.2 submucosa
6 F 1 0.2 submucosa
2 0.5 serosa
3 1.0 serosa
4 0.5 submucosa
7 M 1 1.0 muscularis propria
2 0.2 serosa
3 0.4 muscularis propria
8 F 1 0.5 submucosa
2 1.5 submucosa
3 0.2 submucosa
9 F 1 1.5 submucosa
2 1.5 submucosa
3 2.5 serosa
10 M 1 1.5 submucosa
2 1.0 serosa
3 1.5 muscularis propria
4 1.0 serosa
Total Number 38 14 7 17
Average Size 0.7 0.9 0.5 0.7
To determine the role of increased proliferation in the had spread to distant sites, we analyzed the mesenteric
lymphatics and the enlarged lymph nodes histologically.Smad3 neoplastic process, we assessed expression of
proliferating cell nuclear antigen (PCNA), a marker of Some of the lymphatics were filled with mucin that we
interpret as being produced by adenocarcinoma (Figurecell division. In the colonic tissue adjacent to a colon
cancer, PCNA staining was confined to the base of the 8A). We also found mucin-filled structures at distant
sites including enlarged thoracic lymph nodes (Figurecrypts (Figure 7C). In contrast, enhanced staining, and
hence proliferation, was widespread throughout the tu- 8B). The architecture of these nodes was distorted by
the replacement of the normal lymph tissue with mucinmor tissue (Figure 7D). Therefore, hyperproliferation ap-
pears to be a component of the carcinogenic process produced by adenocarcinoma (Figure 8B). Figures 8C
and 8D demonstrate definitive distant spread of the ade-observed in the Smad3 mutant mice.
nocarcinoma into a lymph node where a metastatic, well
differentiated neoplastic gland was present within theAdenocarcinoma Is Present in Lymph Nodes
In humans with colorectal adenocarcinomas, metastatic afferent lymphatic of the node. Thus, mutation of Smad3
function in mice results in malignant, metastatic trans-spread typically initiates in the lymphatics and then
progresses to involve regional lymph nodes (Fenoglio- formation of colonic epithelium.
Preiser et al., 1989; Cohen et al.,1997; Bresalier and Kim,
1998). We observed macroscopic evidence of enlarged Hybrid (129/Sv 3 C57BL/6) Smad32/2 Mutants
Have Colorectal Cancerlymph nodes in a number of mutant mice (not shown).
This enlargement is consistent with either reactive We also analyzed the Smad3 mutation on a 129/Sv 3
C57BL/6 hybrid genetic background. The heterozygouslymphadenopathy or infiltration by carcinoma. To deter-
mine if the adenocarcinomas in the Smad3 mutant mice animals have been observed for up to nine months with
Smad3 Mutant Mice Develop Colorectal Cancer
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Figure 6. Smad3 Colorectal Neoplasms Display a Spectrum of Shape, Size, and Invasiveness
(A) A histological section shows the thickened neoplastic epithelium in the sessile or plaque-like mass (left) adjacent to normal colonic
epithelium (right).
(B) Higher magnification of section in (A) demonstrated tumor invasion through the submucosa (SM), and the neoplastic epithelial cells (arrow)
abut the underlying muscularis propria. Note the abnormally branched gland (arrow) lined by hyperchromatic cells.
(C) Higher magnification of neoplasia shown in (A) demonstrated an atypical, cystic gland (arrow).
(D) Microscopic appearance of a moderately aggressive neoplasm containing atypical mucin-filled glands.
(E) Higher magnification of the mass shown in (D) showing invasion through the submucosa and into the muscularis propria (MP) (arrow).
(F) Higher magnification of (E), showing abnormal branched glands (arrows) lined by neoplastic epithelial cells. Poorly differentiated glands
(asterisk) were observed, and a mucous lake (ML) was apparent.
(G) Histological section of a highly aggressive neoplasm that occupied virtually the entire circumference of the colon. The colonic lumen is
demarcated by an asterisk.
(H) Higher magnification of section in (G). The branched neoplastic glands are surrounded and separated by a desmoplastic stroma. A mucous
lake was evident in the center of the section.
(I) In a region adjacent to that shown in (H), nested, back-to-back, neoplastic glands were located outside of the serosa.
Scale bars: (A-H), 200 mm; (I), 100 mm.
no apparent abnormalities. Thirty-eight hybrid homozy- the adenocarcinoma is much lower in the hybrid back-
ground, and to date only approximately 30% of the hy-gotes have reached five to eight months of age. Eleven
(30%) of the hybrid homozygotes exhibited distress; brid mice have developed colorectal cancers. These
data provide evidence for the potential importance ofalthough, this occurred over a much broader period of
time than seen in the inbred mice. Similar to what was strain-specific genetic modifying factors in the genesis
of colorectal adenocarcinomas in a Smad3 mutant back-observed in the inbred background, hybrid mutants ex-
hibited distended abdomens, rectal prolapse, and ob- ground.
struction of the gastrointestinal tract (not shown). Histo-
pathological analysis demonstrated similar findings to
those observed in the 129/Sv background with larger Discussion
lesions at the ends of the colon, glandular and cellular
atypia, and invasion through the bowel. However, in the Most forms of human cancer result from the mutation
of multiple oncogenes within the same cell (Kinzler andhybrid background, there was a greater variability in
the time course of disease and the tumors were less Vogelstein, 1996; White, 1998). Tumor suppressor genes
have been implicated as major participants in malig-aggressive and smaller than those present in the inbred
background (not shown). In addition, the penetrance of nancy. The availability of animal models through the
Cell
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Figure 7. The Colorectal Cancers Contain APC and Have Increased Proliferation
(A and B) Immunohistochemistry revealed APC protein expression in the apical-lateral region of colonic epithelium adjacent to a cancer (A).
Within the cancer (B), APC protein is widely distributed.
(C and D) In histologically normal epithelium (C) adjacent to a cancer, proliferation, as marked by PCNA staining (brown nuclei-arrows), was
confined to the base of the crypt. In contrast, within the neoplastic mass (D) PCNA staining, indicating proliferation, was markedly increased
and was present throughout the tumor.
Scale bars: 50 mm.
generation of gene knockouts has revealed many in- humans. In addition, in both mice and humans the can-
cer is limited to the colorectum. Moreover, as in humans,sights into the role of tumor suppressors in the develop-
ment of malignancy. For example, p53 mutant mice de- the majority of the tumors are found at the two ends of
the lower intestine with fewer tumors in between (Fenog-velop spontaneous tumors, primarily of the lymphoid
lineage (Donehower et al., 1992; Jacks et al., 1994a). lio-Preiser et al., 1989; Cohen et al., 1997; Bresalier and
Kim, 1998). This may hint at a fundamental biologicalSurprisingly, other tumor suppressors, like RB and NF-1,
believed to causecancer in humans with single hit kinet- property of colorectal cancer. It is possible that a single
mutation in Smad3, albeit at both alleles, recapitulatesics, do not have such clear roles in mouse models
(Clarke et al., 1992; Jacks et al., 1992, 1994b; Lee et al., the sequence observed for the human disease. Ulti-
mately, the Smad3 mutant mice will be evaluated for1992; Brannan et al., 1994).
In this report, we identify Smad3 as a potent tumor accumulation of other genetic changes such as in p53
or ras.suppressor for colonicepithelium inmice. Inbred Smad3
homozygous mutants uniformly develop colorectal ade- Smad3 is an intracellular transducer of TGFb signals.
TGFb signaling inhibits the growth of many cells includ-nocarcinoma in a temporally defined manner, and me-
tastasic spread of the cancer was detected during the ing colonic epithelium (Derynck, 1994; Liu et al., 1997).
Loss of TGFb signaling has been associated with humansame time interval. Vogelstein and colleagues have pro-
posed a model in which a multistep process underlies colorectal cancer (Polyak, 1996). This includes examples
of TGFb resistance in cancer-derived cells and loss-of-the genesis of colorectal cancer (Kinzler and Vogelstein,
1996). This is thought to occur through an orderly se- function mutations in the TGFb type II receptor, Smad2,
and Smad4 (Markowitz et al., 1995; Wang et al., 1995;quence from normal to hyperplastic epithelium, to ade-
nomas, and then to formation of carcinoma. Ultimately, Eppert et al., 1996; Thiagalingam et al., 1996). Taken
together, these data support a connection between lossthe cancers are altered, and this leads to distant meta-
static spread. Although we have yet to systematically of TGFb signaling and colorectal carcinogenesis.
Mice that harbor genetic inactivations of TGFb signal-analyze the time course of carcinogenesis, the Smad3
mutant mice seem to contain many or all of the stages ing cascade components including all three TGFb ligands,
the TGFb receptor, Smad2, or Smad4 do not developproposed in the human model of colon cancer progres-
sion. The multiple stages, invasiveness, metastasis, and cancer (Shull et al., 1992; Kulkarni et al., 1993; Dickson
et al., 1995; Kaartinen et al., 1995; Oshima et al., 1996;histopathology, are similar in Smad3 mutant mice and
Smad3 Mutant Mice Develop Colorectal Cancer
711
Figure 8. Metastatic Spread of the Adenocarcinomas
(A) Mesenteric lymphatics (asterisks) filled by mucin.
(B) Microscopic view of an enlarged thoracic lymph node. The majority of the normal lymph tissue (arrow) was replaced by mucin (asterisk)
derived from the adenocarcinoma.
(C) Histological section of a mesenteric lymph node that contained a metastatic adenocarcinomatous gland (arrow) in an afferent lymphatic.
(D) Higher magnification of the lymph node of (C) demonstrated that the metastatic gland, containing mucin, was formed by well differentiated
neoplastic epithelial cells.
Scale bars: (A-C), 200 mm; (D), 50 mm.
Sanford et al., 1997; Sirard et al., 1998; Waldrip et al., null mice might be the result of abrogation of the TGFb1
signal.1998; Yang et al., 1998). This is likely the result of the
death of the animals from other causes either in utero or To date, Smad3 mutations have not been detected in
human colorectal cancers (Riggins et al., 1997; Arai etearly in postnatal life. Mice with conditional compound
mutations at the APC and Smad4 loci have recently al., 1998). What might account for the discrepancy be-
tween mice and humans? One possibility is that thebeen reported to exacerbate the intestinal polyposis
observed in the APC mutant mice. However, unlike the present status of human tumor studies may be insuffi-
ciently sensitive to detect a broad spectrum of inactivat-human condition, these tumors were small, did not in-
vade through the muscle layer, were not metastatic, and ing mutations (Riggins et al., 1997). Of note, loss-of-
heterozygosity (LOH) of 15q, the chromosomal locationprimarily arose in the small intestine (Takaku et al., 1998).
Colonic epithelial cells proliferate in the bottom of the of Smad3, had been observed in a subset of human
tumors including colorectal cancers (Wick et al., 1996).crypt and migrate toward the lumen as they transit from
a proliferative to a differentiated state. The TGFb type It is also possible that the function of Smad3 in the
mouse is more similar to the function of Smad2 in hu-II receptor and the TGFb1 ligand are expressed in the
luminal half of the crypt where differentiation occurs mans. Such alternate use of related family members
in different species has precedent, for example, in the(Oshima et al., 1997). The phenotype observed in the
Smad3 mutant mice indicates that inactivation of the ephrin signaling gene family (Krull et al., 1997; Wang
and Anderson, 1997). Smad2 and Smad3 are over 90%TGFb signaling pathway relieves some epithelial cells
from the differentiation signal and, instead, the prolifera- identical at the amino acid level, and in biochemical
experiments they appear to play analogous roles down-tive state is maintained leading to tumor formation. Con-
sistent with this idea, overexpression of Smad3 inhibits stream of the TGFb receptor (Zhang et al., 1996; Liu et
al., 1997; Nakao et al., 1997a, 1997b). Our data indicateproliferation of epithelial cells, and blockade of Smad3
function abrogates the growth inhibitory effects of TGFb that in murine colonic epithelium, Smad2 cannot com-
pensate for this loss of Smad3 function. These data(Zhang et al., 1996; Liu et al., 1997). The pattern of ex-
pression of TGFb1 in the colonic epithelium suggests suggest a unique role for Smad3 in regulating the growth
of colonic epithelium.that the cancer phenotype we observed in the Smad3
Cell
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Molecular Analysis of Smad3 Mutant AlleleWhen carried in the 129/Sv 3 C57BL/6 hybrid genetic
E14.5 embryos were obtained from matings of Smad3 heterozy-background, the Smad3 mutation exhibited a markedly
gotes. Total RNA was isolated and cDNA was synthesized with thereduced penetrance compared to the 129/Sv back- SuperScript system (Gibco). The following primers were designed
ground. The difference in phenotype observed in the to analyze various parts of the Smad3 coding region and b-actin
two genetic backgrounds suggests that 129/Sv mice (59 to 39): P1, CATGTCGTCCATCCTGCC; P3, ATGCACTTGGTGTTC
ACG; P6, CTACCTCCAGTGTTGGTG; P7a, GAATCCGATGTCCCCAhave a permissive genetic configuration for tumorigene-
GCACA; P7b, TGTGCTGGGGACATCGGATTC; P8, TCTAAGACACGsis when Smad3 is inactivated and indicates the pres-
CTGGAACAGCGGATGCT; P9, GGATGGTCGGCTGCAGGTGTCC;ence of modifier loci that may be amenable to identifica- P10, TGTTGAAGGCAAACTCACAGAGC; b-Actin Up, CTAAGGCCAA
tion (Dietrich et al., 1993). CCGTGAAAAGA; b-Actin Down, CAGTAATCTCCTTCTGCATCC.
The availability of a mouse tumor model that has high The Smad3 mutant transcript, encoding the entire open reading
frame, was amplified with primers 1 and 8, purified, and sequenced.penetrance and great similarity tohuman colorectal can-
cer should provide a powerful tool for identifying the
Xenopus Assaysgenetic and molecular alterations that lead to malig-
To generate mRNA encoding the Smad3 mutant peptide, we de-
nancy. Furthermore, Smad3 mutant mice may provide signed specific oligonucleotides that corresponded to the start site
a useful model system for pharmacological trials of pre- and the stop site of the aberrant transcript, flanked by BamHI and
EcoRI linkers, 59 and 39, respectively. The sequences of the primersvention and treatment of colorectal adenocarcinoma.
are listed 59 to 39: upstream, CGCGGATCCGCGCATGTCGTCCATC
CTGCCCTTC; downstream, CCGGAATTCCGGTTCACTCAGGTAG
CCAGGAGGT.Experimental Procedures
The primers were used in PCR, and the fragment was subcloned
into the BamHI and EcoRI sitesof pCS2 and sequenced. The plasmidTargeting Vector
(pCS2-mutSmad3) was linearized with NotI and transcribed in vitroDegenerate oligonucleotides based on conserved sequences
as described (Graff et al., 1996). Two independent pCS2-mutSmad3among Smad proteins were used to amplify an approximately 150
clones were tested with identical results. To make other syntheticbp DNA fragment from mouse E8.5 cDNA as described (Graff et al.,
mRNAs, the pSP64T-derived plasmids containing Smad2, Smad1,1996). A mouse 129/Sv genomic library was screened using this
and Smad5 were linearized and transcribed in vitro (Graff et al.,150 bp DNA fragment as a probe. A positive phage containing an
1996; Suzuki et al., 1997).approximately 15 kb insert was identified. A 2 kb EcoRI-BglII frag-
Xenopus embryos were obtained, microinjected, and cultured,ment was subcloned, and sequenced, and found to contain exon 2
and animal caps were dissected (Graff et al., 1996). Embryos wereof Smad3 (Figure 1A). To generate the 39 arm of the targeting vector,
either uninjected (control) or injected with synthetic mRNA as de-
a 2.7 kb SstI±SstI fragment, located 39 of exon 2, was modified at
scribed in the figure legends. All embryonic stages are according
both ends with NotI linkers and subcloned into the unique NotI site to Nieuwkoop and Faber (1967).
of the plasmid pGKneoTK3.IRESLacZ, and the resulting clone is To evaluate Xenopus embryonic tissues, RNA was extracted and
designated pMad5.8. To generate the 59 arm of the targeting vector, analyzed by RT-PCR as described (Graff et al., 1996). The conditions
a 5.2 kb SstI±SstI fragment was modified with SmaI and SalI linkers for the PCR detection of the transcripts for muscle actin, NCAM,
and subcloned into the unique PmeI-SalI sites of pMad5.8. The 39 EF-1a, and globin were previously described (Graff et al., 1996).
end of the 5.2 kb fragment is 76 bp from the end of the exon 2
coding sequence. The final construct is shown in Figure 1A. Tumor Histology
Homozygous Smad3 mutant mice were sacrificed when they exhib-
ited distress and subjected to standard necropsy. All major organs
Generation of Smad3 Mutant Mice were closely examined under the dissecting microscope, and sam-
SalI-linearized targeting vector (25 mg) was electroporated into R1- ples of each organ were processed into paraffin, sectioned, and
ES cells that were selected in 250 mg/ml G418 and 0.5 mM FIAU. examined histologically. Tumor specimens from the lower intestines
The G418-FIAU-resistant ES colonies were picked and subjected were fixed in 10% formalin overnight, then processed, embedded
to Southern analysis (Figure 1). Positive ES clones were also sub- in paraffin, and 6 mm sections were stained with hematoxylin and
jected to Southern analysis using a 500 bp 39 probe (Figure 1). eosin and photographed.
Four positive ES clones were injected into C57BL/6 blastocysts For immunohistochemistry, paraffin sections were deparaffinized,
and transferred into pseudopregnant ICR female recipients (Charles rehydrated, and blocked in 1.5% normal goat serum for 30 min at
River). The resulting chimeras were bred with C57BL/6 females. room temperature. Sections were incubated with either rabbit anti-
Germline transmission was screened by coat color and confirmed APC C-terminal antibody (Santa Cruz, 1:200), rabbit anti-APC N-ter-
by the same Southern analysis. To obtain the targeted Smad3 allele minal antibody (Santa Cruz, 1:500), or mouse monoclonal anti-PCNA
in an inbred 129/Sv background, a male chimera with 100% germline (proliferating cell nuclear antigen) antibody (Santa Cruz, 1:50) at 48C
transmission was directly bred with 129/Sv females. overnight. The detection of the primary antibodies was done with an
immunoperoxidase system (Vectastain ABC kit, Vector). The stained
sections were then examined and photographed.
Genotype of Smad3 Mutant Mice
Heterozygous Smad3 mice were genotyped by Southern analysis Received May 22, 1998; revised August 13, 1998.
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